Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who are refractory to other treatments.
An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only ...
The externally validated Childhood ITP Recovery Score predicted transient versus persistent ITP. The score also predicted bleeding and response to intravenous immunoglobulins. Prediction scores can ...
This might sound surprising, but getting diagnosed with immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura, or ITP) can come as a relief. You can figure out ITP treatment, of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback